Summit Therapeutics
(NASDAQ:SMMT)
$3.95
0.02[0.51%]
Last update: 9:10AM Get Real Time Here
Why is it moving?
Summit Therapeutics shares are trading higher after the company reported Q1 financial results.
Q1 2024 earnings were released today before the market open
Today's conference call ended over 6 hours ago Click to view the webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Summit Therapeutics Stock (NASDAQ:SMMT), Quotes and News Summary

Summit Therapeutics Stock (NASDAQ: SMMT) stock price, news, charts, stock research, profile.

Open$3.920
Close-
Volume / Avg.1.673M / 2.114M
Day Range3.900 - 4.725
52 Wk Range1.300 - 5.220
Market Cap$2.773B
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
68
Short Interest
26.17%
Days to Cover7.71

Recent News

Director of Lululemon Purchases Shares After Large Drop – Insider Weekends
Key Insights:
Asif Suria
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Avi Kapoor
Akeso Marks Profit Milestone With Swift Rights Issue
Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The next highly anticipated product in the firm’s drug pipeline is ivonescimab, the first PD-1/VEGF bispecific antibody to enter Phase III clinical trials By Molly Wen
The Bamboo Works
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
SMMT
IDYA

FAQ

Q

How do I buy Summit Therapeutics (SMMT) stock?

A

You can purchase shares of Summit Therapeutics (NASDAQ: SMMT) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Summit Therapeutics's (SMMT) competitors?

A

Other companies in Summit Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Avidity Biosciences (NASDAQ:RNA), MoonLake (NASDAQ:MLTX) and SpringWorks Therapeutics (NASDAQ:SWTX).

Q

What is the target price for Summit Therapeutics (SMMT) stock?

A

The latest price target for Summit Therapeutics (NASDAQ: SMMT) was reported by Stifel on Tuesday, March 26, 2024. The analyst firm set a price target for 8.00 expecting SMMT to rise to within 12 months (a possible 70.03% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Summit Therapeutics (SMMT)?

A

The stock price for Summit Therapeutics (NASDAQ: SMMT) is $4.705 last updated Today at May 1, 2024 at 11:41 AM EDT.

Q

Does Summit Therapeutics (SMMT) pay a dividend?

A

There are no upcoming dividends for Summit Therapeutics.

Q

When is Summit Therapeutics (NASDAQ:SMMT) reporting earnings?

A

Summit Therapeutics’s Q1 earnings are confirmed for Wednesday, May 1, 2024.

Q

Is Summit Therapeutics (SMMT) going to split?

A

There is no upcoming split for Summit Therapeutics.

Q

What sector and industry does Summit Therapeutics (SMMT) operate in?

A

Summit Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch